Highlights
- Market Cap
- $6.35B
- Enterprise Value
- $6.32B
- EPS (TTM)
- $0.01
- PE Ratio
- 516.23
- PEG Ratio
- 7.54
- Total Revenue (TTM)
- $116.59M
- Gross Profit (TTM)
- $111.17M
- EBITDA (TTM)
- $14.02M
- Year Range
- $6.11 - $11.78
- Target Price
- $16.00
- ROA (TTM)
- 3.03%
- ROE (TTM)
- 4.74%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Gyre Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Gyre Therapeutics Inc (GYRE) has returned -1.27% so far this year and -9.72% over the past 12 months. Over the last ten years, GYRE has returned -32.92% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Gyre Therapeutics Inc
- 1D
- 1.90%
- 1M
- -15.41%
- YTD
- -1.27%
- 6M
- -6.57%
- 1Y
- -9.72%
- 3Y*
- 30.94%
- 5Y*
- -38.61%
- 10Y*
- -32.92%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Apr 12, 2006, GYRE's average daily return is +0.09%, while the average monthly return is +1.26%. At this rate, your investment would double in approximately 4.6 years.
Historically, 45% of months were positive and 55% were negative. The best month was Jul 2009 with a return of +338.0%, while the worst month was Sep 2022 at -74.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, GYRE closed higher 47% of trading days. The best single day was May 23, 2022 with a return of +234.2%, while the worst single day was Sep 21, 2022 at -74.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.59% | 1.85% | -15.41% | -1.27% | |||||||||
| 2025 | -4.88% | 0.78% | -33.45% | 26.42% | -7.07% | -18.96% | -4.08% | 9.79% | -3.62% | 3.89% | -0.00% | -8.90% | -41.65% |
| 2024 | -51.85% | 46.65% | -3.64% | -10.76% | -27.18% | 5.02% | 21.29% | -4.84% | -8.93% | 14.04% | -12.52% | -3.28% | -52.90% |
| 2023 | -46.64% | 5.51% | -30.30% | 2.42% | 3.77% | 59.82% | 7.79% | 47.68% | -13.83% | -6.97% | 249.48% | 9.23% | 224.68% |
| 2022 | -36.54% | 11.90% | 1.69% | -27.42% | 158.87% | 43.55% | -1.69% | 12.57% | -74.42% | 7.16% | 3.24% | -5.40% | -42.29% |
| 2021 | -10.46% | 6.73% | -16.42% | 0.00% | -15.28% | 1.41% | -6.00% | 12.53% | -10.26% | -19.95% | -63.53% | -23.83% | -85.52% |
Benchmark Metrics
Gyre Therapeutics Inc has an annualized alpha of 8.83%, beta of 1.47, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since April 13, 2006.
- This stock participated in 207.53% of S&P 500 Index downside but only 65.76% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8.83%
- Beta
- 1.47
- R²
- 0.06
- Upside Capture
- 65.76%
- Downside Capture
- 207.53%
Return for Risk
Risk / Return Rank
GYRE ranks 32 for risk / return — below 32% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Gyre Therapeutics Inc (GYRE) and compare them to a chosen benchmark (S&P 500 Index).
| GYRE | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.13 | 0.90 | -1.02 |
Sortino ratioReturn per unit of downside risk | 0.36 | 1.39 | -1.02 |
Omega ratioGain probability vs. loss probability | 1.04 | 1.21 | -0.17 |
Calmar ratioReturn relative to maximum drawdown | -0.56 | 1.40 | -1.96 |
Martin ratioReturn relative to average drawdown | -0.77 | 6.61 | -7.38 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore GYRE risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Gyre Therapeutics Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $896.49 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 127.30% |
Monthly Dividends
The table displays the monthly dividend distributions for Gyre Therapeutics Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Gyre Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Gyre Therapeutics Inc was 99.99%, occurring on Mar 20, 2023. The portfolio has not yet recovered.
The current Gyre Therapeutics Inc drawdown is 99.98%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.99% | Mar 4, 2011 | 3031 | Mar 20, 2023 | — | — | — |
| -84.89% | Jul 30, 2007 | 340 | Dec 1, 2008 | 164 | Jul 28, 2009 | 504 |
| -38.22% | Apr 13, 2006 | 107 | Sep 15, 2006 | 71 | Dec 27, 2006 | 178 |
| -25.89% | May 4, 2010 | 81 | Aug 26, 2010 | 41 | Oct 25, 2010 | 122 |
| -21.7% | Dec 7, 2009 | 69 | Mar 17, 2010 | 29 | Apr 28, 2010 | 98 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Gyre Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Gyre Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for GYRE, comparing it with other companies in the Biotechnology industry. Currently, GYRE has a P/E ratio of 516.2. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for GYRE compared to other companies in the Biotechnology industry. GYRE currently has a PEG ratio of 7.5. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GYRE relative to other companies in the Biotechnology industry. Currently, GYRE has a P/S ratio of 22.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GYRE in comparison with other companies in the Biotechnology industry. Currently, GYRE has a P/B value of 59.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |